Clik here to view.
LegoChem Biosciences and Amgen Enter into a Multi-Target Research...
DAEJEON, South Korea LegoChem Biosciences, Inc. (‘LCB’) (KOSDAQ:141080) announced on December 23 that it has entered into a research collaboration and license agreement with Amgen, whereby it...
View ArticleClik here to view.
InnoCare Announces Approval of Tafasitamab in Combination With Lenalidomide...
BEIJING InnoCare Pharma (HKEX: 09969; SSE: 688428) announced today the approval of tafasitamab in combination with lenalidomide for adult patients with relapsed or refractory diffuse large B-cell...
View ArticleClik here to view.
BeiGene Announces Acceptance of 12th Regulatory Submission in China for PD-1...
CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company announced that the Center for Drug Evaluation (CDE) of the...
View ArticleClik here to view.
Legend Biotech Announces Acceptance of Its New Drug Application for...
SOMERSET, N.J. Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening...
View ArticleClik here to view.
PharmaEssentia to Present at the 41st Annual J.P. Morgan Healthcare Conference
TAIPEI, Taiwan PharmaEssentia Corporation (TPEx:6446), a global biopharmaceutical innovator leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and...
View ArticleClik here to view.
Establishment Labs Announces Seishin Plastic and Aesthetic Surgery Clinic in...
SANTA BARBARA, Calif. Establishment Labs Holdings Inc. (Nasdaq: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and...
View ArticleClik here to view.
JS InnoPharm Initiates Treatment With JSI-1187, a Selective ERK Inhibitor, in...
CHICAGO & SHANGHAI JS InnoPharm Ltd initiated the JSI-1187 plus dabrafenib combination dose-escalation phase of the Phase 1 study for patients with locally advanced or metastatic solid tumors...
View ArticleClik here to view.
CANbridge Consolidates Gene Therapy Portfolio
BEIJING & BURLINGTON, Mass. CANbridge Pharmaceuticals, Inc. (1228.HK), a global biopharmaceutical company, with a foundation in China, committed to the research, development and...
View ArticleClik here to view.
BeiGene to Present at the J.P. Morgan 41st Annual Healthcare Conference
CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company today announced that the Company will participate in the J.P....
View ArticleClik here to view.
Elpiscience to Present Its Novel Immunotherapies at Biotech Showcase™ during...
SHANGHAI & SUZHOU, China & GERMANTOWN, Md. Elpiscience Biopharmaceuticals, Inc. (“Elpiscience”), a clinical-stage biopharmaceutical company dedicated to discovering and developing...
View ArticleClik here to view.
PharmaEssentia Establishes a New Research and Development Facility in the...
TAIPEI,Taiwan PharmaEssentia Corporation, (TPEx:6446), a global biopharmaceutical innovator headquartered in Taiwan leveraging deep expertise and proven scientific principles to deliver new...
View ArticleClik here to view.
知临集团宣布发表其 PathsDx 技术的合作论文——PathsDx 技术是一种快速周转的低深度无偏倚宏基因组学测序工作流程，可在 Illumina...
NEW YORK & LONDON & PARIS 知临集团有限公司（纳斯达克股票代码：APM，巴黎泛欧证券交易所股票代码：APM）是一家临床阶段的生物制药公司，致力于解决肿瘤学、自身免疫性疾病和传染病领域未满足的医疗需求。知临集团很高兴地宣布其最新联合发布了一篇论文，评估Illumina 平台上的快速周转低深度无偏倚宏基因组测序工作流程。该项名为 PathsDx Test...
View ArticleClik here to view.
Aptorum Group Announces Publication of a Co-authored Paper on its PathsDx...
NEW YORK & LONDON & PARIS Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) a clinical stage biopharmaceutical company dedicated to tackling unmet medical needs in...
View ArticleClik here to view.
InnoCare to Present Latest Clinical Data of Gunagratinib at the Upcoming 2023...
BEIJING InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Company will present the...
View ArticleClik here to view.
Takeda Announces Favorable Phase 3 Safety and Efficacy Results of TAK-755 as...
OSAKA, Japan & CAMBRIDGE, Mass. Takeda (TSE:4502/NYSE:TAK) today announced that the totality of evidence from a pre-planned interim analysis of a pivotal Phase 3 study supports the efficacy and...
View ArticleClik here to view.
Clik here to view.
Genexine to Present Final Phase 2 Clinical Data on Its Cervical Cancer...
SEOUL, South Korea Genexine (KOSDAQ: 095700), a publicly traded, clinical-staged Korean biopharmaceutical company committed to the discovery and development of novel biologics for the treatment of...
View ArticleClik here to view.
Twist Bioscience、アステラス製薬と複数標的抗体発見に関する共同研究契約を締結
カリフォルニア州サンフランシスコ （ビジネスワイヤ） — シリコンプラットフォームを用いた高品質な合成DNAの提供を通じて顧客の成功を支援するTwist Bioscience Corporation（NASDAQ: TWST、以下「Twist社」）は、アステラス製薬株式会社（TSE:...
View ArticleClik here to view.
Twist Bioscience and Astellas Enter into Multitarget Antibody Discovery...
SOUTH SAN FRANCISCO, Calif. Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today...
View ArticleClik here to view.
STAAR Surgical Reports Preliminary Sales for Fourth Quarter and Fiscal 2022
LAKE FOREST, Calif. STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today reported preliminary sales for the fourth quarter...
View Article